Dr. Rivero on Monocytic Differentiation in AML
Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.
Gustavo Rivero, MD, associate professor, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses evolving therapies for patients with acute myeloid leukemia (AML) with monocytic differentiation.
The current standard of care for patients with AML who are ineligible for intensive chemotherapy is the combination of a hypomethylating agent (HMA) and venetoclax (Venclexta), Rivero says. However, patients with monocytic differentiation often display inferior responses to this regimen, Rivero explains.
Recent evidence suggests that AML with monocytic differentiation can have lower BCL-2 expression and higher MCL-1 expression, potentially explaining their resistance to HMAs and venetoclax and serving as prognostic markers.
Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.
